Vaxart's adjourned meeting highlights urgent need for reverse stock split to maintain Nasdaq listing amid apparent low price challenges. The adjournment of Vaxart's stockholder meeting reveals a critical compliance issue with Nasdaq's minimum bid price requirement. This postponement strongly suggests insufficient shareholder support for the proposed reverse stock split (Proposal No. 2), which management deems necessary to maintain Nasdaq listing. This situation typically indicates the company's share price has fallen below $1 for an extended period. The language in the announcement - particularly the unusual step of explicitly listing benefits of approving the reverse split and encouraging those who voted against it to change their votes - signals management's heightened concern about securing approval.